Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 1
1981 1
1982 1
1983 4
1984 2
1986 4
1987 5
1988 7
1989 6
1990 4
1991 5
1992 7
1993 4
1994 5
1995 24
1996 5
1997 3
1998 4
1999 5
2000 7
2001 7
2002 7
2003 9
2004 7
2005 11
2006 13
2007 11
2008 11
2009 4
2010 8
2011 8
2012 12
2013 19
2014 16
2015 13
2016 6
2017 17
2018 24
2019 33
2020 29
2021 38
2022 34
2023 33
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

451 results

Results by year

Filters applied: . Clear all
Page 1
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
Spigel DR, Dowlati A, Chen Y, Navarro A, Yang JC, Stojanovic G, Jove M, Rich P, Andric ZG, Wu YL, Rudin CM, Chen H, Zhang L, Yeung S, Benzaghou F, Paz-Ares L, Bunn PA; RESILIENT Trial Investigators. Spigel DR, et al. J Clin Oncol. 2024 Apr 22:JCO2302110. doi: 10.1200/JCO.23.02110. Online ahead of print. J Clin Oncol. 2024. PMID: 38648575
Do Transtibial Amputations Outperform Amputations of the Hind- and Midfoot Following Severe Limb Trauma?: A Secondary Analysis of the OUTLET Study.
Fram BR, Bosse MJ, Odum SM, Reider L, Gary JL, Gordon WT, Teague D, Alkhoury D, MacKenzie EJ, Seymour RB, Karunakar MA; The Major Extremity Trauma Research Consortium. Fram BR, et al. J Bone Joint Surg Am. 2024 May 1;106(9):776-781. doi: 10.2106/JBJS.23.00878. Epub 2024 Mar 21. J Bone Joint Surg Am. 2024. PMID: 38512987
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. Janjigian YY, et al. Among authors: schenker m. J Clin Oncol. 2024 Feb 21:JCO2301601. doi: 10.1200/JCO.23.01601. Online ahead of print. J Clin Oncol. 2024. PMID: 38382001
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, Menezes J, Reinmuth N, Richardet E, Cheng Y, Mizutani H, Felip E, Zurawski B, Alexandru A, Paz-Ares L, Lu S, John T, Zhang X, Mahmood J, Hu N, De T, Santi I, Penrod JR, Yuan Y, Lee A, Reck M. Carbone DP, et al. Among authors: schenker m. J Immunother Cancer. 2024 Feb 12;12(2):e008189. doi: 10.1136/jitc-2023-008189. J Immunother Cancer. 2024. PMID: 38346853 Free PMC article. Clinical Trial.
451 results